• Syringin Targets EGFR/PI3K/Akt to Overcome RCC Drug Resistan

  2026-08-01

  This study uncovers the mechanistic role of Syringin, a natural product, in inhibiting renal cell carcinoma (RCC) cell proliferation and enhancing apoptosis via modulation of the EGFR/PI3K/Akt pathway. Notably, Syringin increases RCC cell sensitivity to sunitinib, suggesting a novel strategy to address drug resistance and improve targeted therapy outcomes.

• Autophagy-Metastasis Prognostic Signature in Colorectal Canc

  2026-07-31

  Bai et al. (2026) introduce a validated prognostic risk signature for colorectal cancer (CRC) that integrates autophagy and liver metastasis gene expression using bulk and single-cell transcriptomic data. This innovation enables better prediction of patient outcomes and highlights the immunosuppressive mechanisms that drive therapeutic resistance, shaping future directions in CRC immunotherapy and biomarker development.

• DAPT (GSI-IX): Optimizing Notch Signaling in Disease Models

  2026-07-31

  DAPT (GSI-IX) enables precise, reproducible inhibition of γ-secretase, unlocking advanced studies in Notch signaling, neurodegeneration, and angiogenesis. Its robust experimental versatility and well-characterized inhibition profile make it a trusted choice for dissecting cell fate pathways and modeling disease mechanisms.

• Sulfo-Cy5 NHS Ester: Illuminating Immune Microenvironments

  2026-07-30

  This thought-leadership article explores how Sulfo-Cy5 NHS ester advances the precision and impact of translational immune microenvironment research. Integrating mechanistic insights from recent tumor immunology breakthroughs with practical guidance, we reveal how this next-generation fluorescent probe empowers researchers to dissect complex cellular interactions and overcome analytical limitations inherent to conventional dyes. Strategic recommendations and protocol parameters are provided to facilitate robust, reproducible protein conjugation for high-resolution imaging of immune function.

• SETD7 Depletion Promotes White Adipose Browning and Improves

  2026-07-30

  This study uncovers SETD7 as a negative regulator of white adipose tissue (WAT) browning, demonstrating that its depletion enhances thermogenic gene expression and protects mice from obesity-related metabolic disorders. The findings offer mechanistic insight into adipocyte thermogenesis and highlight SETD7 as a promising target for metabolic disease intervention.

• 2,7-Dichlorodihydrofluorescein Diacetate for Reliable ROS De

  2026-07-29

  2,7-Dichlorodihydrofluorescein diacetate (DCFH-DA) empowers researchers with sensitive, reproducible intracellular ROS assessment across microscopy, flow cytometry, and high-throughput assays. Recent advances reveal how tailoring protocol parameters and troubleshooting strategies unlocks its full potential for mitochondrial dysfunction and oxidative stress studies.

• Ajugol Enhances Mitophagy to Suppress Pyroptosis in Gouty Ar

  2026-07-29

  This study reveals that ajugol alleviates acute gouty arthritis by restoring mitophagy and inhibiting chondrocyte pyroptosis via suppression of the PI3K/Akt/mTOR pathway. The findings highlight a mitochondrial-targeted mechanism for inflammation control, providing a framework for future research into targeted interventions in arthritic and related inflammatory diseases.

• n-Dodecyl-β-D-maltoside: Advancing Integrin Structural Biolo

  2026-07-28

  n-Dodecyl-β-D-maltoside (DDM) is the gold standard for gentle solubilization and stabilization of membrane proteins, enabling high-resolution cryo-EM studies and robust protein–lipid interaction assays. This article delivers actionable protocols and troubleshooting insights for maximizing DDM’s unique properties—empowering researchers to decode complex membrane protein structures like integrin αvβ3 with unprecedented fidelity.

• Elevating ROS Detection in Translational Oncology: Strategic

  2026-07-28

  This thought-leadership article provides translational researchers with an advanced perspective on leveraging 2',7'-Dichlorofluorescein diacetate (DCFDA) for robust intracellular ROS measurement, especially within the context of nanomedicine-driven cancer therapy. By integrating mechanistic detail, competitive analysis, and strategic workflow guidance—anchored in recent breakthroughs in self-adaptive nanocarrier systems—this piece positions DCFDA as a cornerstone tool for decoding oxidative stress in complex in vitro and ex vivo models.

• Triiodothyronine (T3) in Adipose Browning: Mechanistic Insig

  2026-07-27

  Explore the advanced mechanistic roles of Triiodothyronine (T3) in adipose tissue browning and metabolic regulation. This article delivers original, evidence-based guidance for researchers using T3 in metabolic disorder models, highlighting protocol strategies and recent breakthroughs in thyroid hormone signaling pathways.

• Phosbind Acrylamide for High-Fidelity Phosphorylation Analys

  2026-07-27

  Discover how Phosbind Acrylamide transforms phosphate-binding assays by enabling precise, antibody-free protein phosphorylation analysis. Gain new insights into workflow optimization and assay accuracy for signal transduction studies.

• Exemestane: Steroidal Aromatase Inhibitor for Breast Cancer

  2026-07-26

  Exemestane is a potent, irreversible steroidal aromatase inhibitor that enables robust estrogen biosynthesis inhibition in advanced breast cancer models. This article provides actionable protocols, troubleshooting strategies, and translational insights to optimize its use in hormone-dependent research settings.

• Mianserin HCl: Protocol Innovations for 5-HT2 Antagonist Res

  2026-07-25

  Mianserin HCl, a high-purity 5-HT2 receptor antagonist, empowers researchers with unique opportunities for targeted antidepressant and antipathogenic assays. Advanced workflows exploiting cyclodextrin complexation and validated protocol parameters enable high-precision studies in neuroscience and psychiatric disorder research.

• Purmorphamine: Advanced Smo Agonism for Osteogenic & Sensory

  2026-07-24

  Explore how Purmorphamine, a potent Smoothened agonist, uniquely enables advanced research into Hedgehog pathway modulation—from osteoblast differentiation to insect sensory biology. Discover actionable protocol strategies and new scientific insights not covered elsewhere.

• Low-Molecular Weight Inhibitors of the Alternative Complemen

  2026-07-24

  Schubart et al. provide a comprehensive review of the discovery and development of low-molecular weight (LMW) inhibitors targeting the alternative complement pathway, with a focus on oral agents against factor B and factor D. Their work elucidates the mechanistic rationale, therapeutic potential, and translational challenges of these inhibitors for diseases characterized by complement dysregulation.

446 records 9/30 page Previous Next First page 上5页 678910 下5页 Last page